And the status of a lot of people's health insurance is suddenly up in the air.
> Newly approved cancer drugs cost an average of $10,000 per month, with some therapies topping $30,000 per month, according to ASCO, which discussed the costs of cancer care at a recent meeting. Just a decade ago, the average cost per month of new drugs was about $4,500.
It seems $4,000 is rather a small fee in comparison.
But then those people wouldn't be able to afford other treatments either.
" Two infants with relapsed refractory CD19+ B cell acute lymphoblastic leukemia received lymphodepleting chemotherapy and anti-CD52 serotherapy, followed by a single-dose infusion of UCART19 cells"[1]
With that context, it's potentially cheaper than other therapies.
with regards to the mention of other companies more complex methods, perhaps its merely reminding people that complex solutions are not always the only way
Gleevec and Sprycel are the canonical examples of "competition makes the price go up" but if a single payer dominated the market and used this as leverage, it would be simple enough to just say "not at that price" and force manufacturers to play ball. The real problem is regulatory and legislative capture which prevents this from happening.